Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares during the specified Class Period, highlighting potential misrepresentation regarding clinical trial outcomes [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to investors who acquired Mereo securities from June 5, 2023, to December 26, 2025, with a deadline of April 6, 2026, for potential lead plaintiff appointments [2]. - The defendants allegedly made overly positive statements about the ORBIT and COSMIC Phase 3 clinical trials for setrusumab, aimed at treating Osteogenesis Imperfecta [3]. Group 2: Impact of Disclosure - On December 29, 2025, Mereo disclosed that neither clinical trial achieved its primary endpoint, resulting in a significant drop of over 87% in the price of its ADS, from $2.31 per share to $0.29 per share [4].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of ASP Isotopes Inc. regarding potential breaches of fiduciary duties by the Company and certain officers [1] Group 1: Legal Investigation - The investigation is focused on whether ASP Isotopes and its executives breached their fiduciary duties to shareholders [1] - Shareholders who acquired ASP Isotopes securities prior to September 26, 2024, can seek corporate reforms and a court-approved incentive award at no cost [2][6] Group 2: Securities Fraud Allegations - A securities fraud class action complaint against ASP Isotopes was allowed to proceed after a partial denial of the defendants' motion to dismiss by the United States District Court for the Southern District of New York [3] - The complaint alleges that from September 2024, the Company made false statements regarding its uranium enrichment capabilities, claiming it had proprietary technology that was never tested [4] - These misrepresentations allegedly helped the Company raise approximately $18.6 million in gross proceeds while inflating its stock price [5]

Group 1 - A class action lawsuit has been filed against Richtech Robotics Inc. on behalf of investors who purchased securities during the period from January 27, 2026, to January 29, 2026 [1][2] - The lawsuit alleges that Richtech misled investors about its business relationship with Microsoft, which was revealed to be a standard customer program without commercial elements [3] - Following the revelation, Richtech's stock price fell from $5.08 per share on January 28 to $4.02 per share on January 29, and further down to $3.58 per share on January 30, marking a total decline of nearly 30% [3] Group 2 - Richtech Robotics is based in Las Vegas and specializes in designing and manufacturing AI-enabled service robots for the restaurant and hospitality industries [2] - Berger Montague, the law firm representing the plaintiffs, is known for its focus on complex civil litigation and has recovered over $50 billion for clients over its 55-year history [5]

Core Viewpoint - The Soleno Therapeutics, Inc. class action lawsuit alleges that the company and its executives failed to disclose significant safety concerns related to their only commercial product, DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [3][4][5]. Group 1: Class Action Details - The class action lawsuit is titled "City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc." and allows purchasers of Soleno common stock between March 26, 2025, and November 4, 2025, to seek appointment as lead plaintiff by May 5, 2026 [1]. - The lawsuit claims that Soleno's Phase 3 clinical trial for DCCR downplayed and concealed safety concerns, including issues related to excess fluid retention [3]. - Allegations include that DCCR posed greater safety risks than disclosed, leading to lower commercial viability and potential adverse events post-launch [3]. Group 2: Impact of Reports and Financial Results - On August 15, 2025, a critical report by Scorpion Capital LLC led to a nearly 12% decline in Soleno's stock price over two trading days [4]. - Following a report of a patient death after taking DCCR on September 10, 2025, Soleno's stock price dropped approximately 19% over two trading days [5]. - The financial results for the third fiscal quarter ended September 30, 2025, indicated that the Scorpion Capital report disrupted DCCR's launch trajectory, resulting in fewer patient start forms and increased discontinuations, causing a 27% decline in stock price [6].

Core Viewpoint - Kaskela Law is investigating e.l.f. Beauty, Inc. for potential securities fraud on behalf of long-term shareholders, following allegations of misleading statements made by the company's executives regarding product demand and sales growth [1][2][5]. Group 1: Allegations and Complaints - A securities fraud complaint was filed against e.l.f. Beauty for misleading investors about the demand for its products during the Class Period from February 7, 2024, to February 6, 2025 [2]. - The complaint highlights that on August 8, 2024, e.l.f. disclosed weaker-than-expected guidance, leading to a significant drop in share price by $27.12, or over 14%, closing at $160.83 on August 9, 2024 [3]. - On February 6, 2025, e.l.f. reported that net sales growth for Q4 FY 2025 would be between -1% and 2%, marking the worst sales growth quarter in six years, which caused shares to fall an additional $17.36, or nearly 20%, closing at $71.13 on February 7, 2025 [4]. Group 2: Investigation and Legal Rights - Kaskela Law is investigating whether e.l.f.'s board of directors violated securities laws or breached fiduciary duties, which may have led to investor losses [5][8]. - Long-term shareholders of e.l.f. who acquired shares prior to February 7, 2024, are encouraged to contact Kaskela Law to discuss their legal rights and options [6].

Core Viewpoint - Richtech Robotics Inc. is facing a class action lawsuit for allegedly misleading investors about its relationship with Microsoft, which has resulted in significant stock price declines [3][4]. Group 1: Lawsuit Details - The class action lawsuit, titled Diez v. Richtech Robotics Inc., is open for investors who purchased Richtech Robotics securities between January 27, 2026, and January 29, 2026, to seek appointment as lead plaintiff [1]. - The lawsuit alleges that Richtech Robotics falsely claimed a commercial relationship with Microsoft during the class period [3]. - Following the publication of an article by Hunterbrook Media on January 29, 2026, which denied any partnership with Microsoft, Richtech Robotics' Class B stock price fell by over 29% within two trading days [4]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Richtech Robotics securities during the class period to seek lead plaintiff status, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [5]. Group 3: Company Background - Richtech Robotics specializes in developing, manufacturing, deploying, and selling robotic solutions for automation in the service industry [2].

Core Viewpoint - The Trip.com Group Limited is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and failure to disclose regulatory risks associated with its monopolistic practices [1][4]. Company Overview - Trip.com operates as a travel service provider, offering services such as accommodation reservations, transportation ticketing, packaged tours, in-destination services, corporate travel management, and other travel-related services [3]. Allegations - The lawsuit alleges that during the class period, Trip.com and its executives made false or misleading statements and failed to disclose the regulatory risks stemming from their monopolistic business activities [4]. - A significant event occurred on January 14, 2026, when Bloomberg reported that China was investigating Trip.com for alleged antitrust conduct, which led to a 19% drop in the price of Trip.com American Depositary Shares over two trading sessions [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Trip.com securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Viewpoint - Atara Biotherapeutics, Inc. is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its product tabelecleucel and associated manufacturing issues [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Atara Biotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Atara's securities between May 20, 2024, and January 9, 2026, are encouraged to participate in the lawsuit before May 22, 2026 [2]. - The lawsuit claims that Atara made false statements about its manufacturing capabilities and the likelihood of FDA approval for tabelecleucel, leading to investor losses when the truth was revealed [4]. Group 2: Company Issues - Atara is reported to have faced significant manufacturing problems and deficiencies in its ALLELE study, which raised concerns about regulatory approval [4]. - The company allegedly overstated the prospects of its product tabelecleucel, which contributed to the misleading public statements [4]. - The lawsuit indicates that Atara's public statements were materially misleading throughout the class period, resulting in damages to investors when the actual situation became known [4].

Core Viewpoint - Super Micro Computer, Inc. is facing a class action lawsuit due to alleged securities fraud that occurred between April 30, 2024, and March 19, 2026, which has resulted in significant financial losses for investors [2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud during the specified period [2]. - Super Micro and certain executives are accused of failing to disclose material information, violating federal securities laws [3]. - An indictment was unsealed against three individuals associated with the company for diverting servers containing U.S. AI technology to China, violating U.S. export control laws, and generating approximately $2.5 billion in sales from 2024 to 2025 [4]. Group 2: Market Reaction - Following the announcement of the indictment, Super Micro's share price dropped by $10.26, or 33.3%, closing at $20.53 per share on March 20, 2026 [5]. Group 3: Legal Process - Investors in Super Micro have until May 26, 2026, to request to be appointed as lead plaintiff in the class action lawsuit, although participation in any recovery does not require serving as a lead plaintiff [5].

Core Viewpoint - The Super Micro class action lawsuit alleges that the company and its executives violated the Securities Exchange Act of 1934 by making misleading statements and failing to disclose significant compliance issues related to U.S. export control laws [1][4]. Company Overview - Super Micro Computer, Inc. develops and sells server and storage solutions based on modular and open-standard architecture [3]. Allegations of the Lawsuit - The lawsuit claims that a significant portion of Super Micro's server sales were made to companies in China, which violated U.S. export control laws [4]. - It is alleged that there were material weaknesses in Super Micro's compliance controls regarding applicable export control laws and regulations [4]. - The U.S. Department of Justice announced an indictment against three individuals associated with Super Micro for diverting servers containing U.S. artificial intelligence technology to China, resulting in approximately $2.5 billion worth of sales between 2024 and 2025 [5]. Impact on Stock - Following the DOJ announcement, Super Micro's stock price fell by more than 33% [5]. Legal Process - Investors who purchased Super Micro securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, with the lead plaintiff representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7].